MONTREAL, Feb. 6, 2026 /CNW/ - Novartis Canada applauds Canada's Drug Agency (CDA-AMC) for its positive draft recommendation to reimburse Kisqali® (ribociclib tablets) for all eligible early breast cancer (eBC) patients at high risk of recurrence.1
Read more at newswire.ca
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Kisqali® Receives Positive Draft Recommendation From Canada's Drug Agency For All Eligible Early Breast Cancer Patients at High Risk of Recurrence
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
